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Abstract
OBJECTIVE—To compare Websites of agencies that broker the services women who provide 
human eggs for in vitro fertilization versus clinics that recruit egg providers.
STUDY DESIGN—We examined 207 websites, of which 128 were egg provider agency (40%) 
or clinic (60%) websites that recruited providers online. We compared them regarding several 
variables related to adherence to American Society for Reproductive Medicine (ASRM) 
guidelines.
RESULTS—According to their respective websites, agencies were more likely than clinics to 
mention ASRM guidelines, be located in the West/Pacific, indicate compensation, offer a fee 
range, set their minimum > $5,000, specify preferable traits, cap provider age at ≤ 31,require an 
education minimum, allow both parties to meet, discuss short-term risks, and not acknowledge a 
possible cancer risk. Only 25.5% of agencies and 19.5% of clinics mention psychological/
emotional risks, and 11.8% and 5.2%, respectively, mention risks, to future fertility.
CONCLUSIONS—This research, the first to systematically compare several key aspects of egg 
provider agencies versus clinics, suggests significant differences in adherence to guidelines, 
raising several concerns and suggesting needs for consideration of improved monitoring and 
regulation by ASRM or others.
Keywords
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Over the past two decades, freestanding, for-profit agencies that broker the services of 
young women who are willing to provide their eggs to infertile women have proliferated in 
the United States,1–3 but little is known about their practices. Agencies have been defined as 
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“brokers hiring the egg donors and matching them to recipients.”3 These entities often act as 
the “middle man” between the egg provider and the recipient or, in other cases, between the 
egg provider and IVF clinics in need of agencies’ anonymous services. Some IVF clinics 
work with agencies to identify and engage egg provid-ers, while other clinics have their own 
recruitment and matchmaking programs.4 But many questions about these agencies remain.
Beyond the U.S. Food and Drug Administration’s rules concerning reproductive tissue 
donation, federal regulations currently do not cover the recruitment of egg providers. 
Clinics, unlike agencies, are typically members of the American Society for Reproductive 
Medicine (ASRM) and are owned and operated by licensed physicians who are bound by 
professional ethical codes.5 But egg agencies are typically commercial entities, owned and 
Operated by individuals with a variety of backgrounds who do not necessarily have any 
formal licensing or professional training, and hence are not necessarily bound by any 
medical over-sight.3 Therefore, unique questions arise: whether agencies should fit into the 
U.S. model of self-regulation of assisted reproductive technologies (ARTs) and, if so, how.4
Agencies do not perform any of the medial procedures involved in oocyte donation (e.g., 
administering medication or conducting the actual retrieval), but may play pivotal roles in 
recruiting, educating and compensating egg providers. These activities are important and are 
the subject of ASRM’s ethical guidelines.6 The recruitment process can strongly shape egg 
providers’ initial impressions about the process. Increasingly, websites are a major venue for 
healthcare information and services, including egg provider recruitment.7,8 Such initial 
contact and framing of information undoubtedly influences how women perceive the act of 
providing gametes and can even be seen as the first step in the informed consent process, 
since first impressions often impact later decision-making.7
The amount of compensation offered is important, and controversial. Many Western 
countries ban compensating egg providers.4,9 Currently, ASRM is facing a lawsuit brought 
by an egg provider for alleged price-fixing.10 The practice of egg provision has been 
controversial since its inception nearly 30 years ago and continues to be debated, involving 
several ethical issues (i.e., appropriate informed consent, possible long-term risks to egg 
providers, exploitation of egg providers, commodification of human life, and the right of 
children born from provider eggs to know their genetic lineage).11–17 In certain ways, youn 
providers may constitute a vulnerable group since they face risks of ovarian 
hyperstimulation syndrome (OHSS)18 and possible impediments in their ability to bear 
children in the future.19,20 ASRM guidelines address several of these topics, stating that 
compensation should reflect the “time, inconvenience, and discomfort” associated with the 
egg donation process, which should be “…distinguished from payment for oocytes 
themselves, and compensation should not vary according to…the outcome of prior donation 
cycles, or the donor’s ethnic or other personal characteristics.”6
Additionally,
To discourage improper decisions to donate oocytes, [donors should] receive 
accurate and meaningful information on the potential physical [and] psychological 
effects of oocyte retrieval and donation. … It would be prudent to limit donors to 
those who are 21 or older, and advertisements for donors [should be] accurate and 
Holwell et al. Page 2









responsible…[such that] if financial…benefits are noted…the existence of risks 
and burdens also…[are] acknowledged.6
We have previously reported on adherence to these guidelines across all websites recruiting 
egg providers (i.e., clinics and agencies combined) and found several areas of 
noncompliance in regards to compensation structure, presentation of risks, and age 
minimums for recruitment.1 We examined how a subset of agencies and clinic websites that 
discussed compensation (N=102) compare regarding a single characteristic––trait-based 
payment.1 We found that agencies are more likely than clinics to mention explicitly paying 
more for certain donor traits, or to state that these were preferred or in demand. Yet, many 
other important questions and aspects of these entities’ practices exist that we did not 
compare and that remain unexplored (e.g., whether agency and clinic websites differ in 
presenting risks, requirements to provide eggs, anonymity, long-term privacy, and 
compensation structure). These other potential differences are important in understanding 
whether agencies and clinics differ in additional ways and, if so, how.
These distinctions between agencies and Society for Assisted Reproductive Technology 
(SART)–registered IVF clinics are critical, as ASRM does not oversee these organizations. 
Similarly, ASRM can revoke physicians’ membership in its professional society for 
noncompliance with published guidelines, a result which would likely damage the 
provider’s and clinic’s reputation and perhaps limit access to professional networks. 
Agencies, however, are stand-alone businesses that face no substantive legal or professional 
consequences for not complying with guidelines. To increase compliance among agencies, 
ASRM did arrange for voluntary agreements, whereby agencies could choose to state that 
they will abide by ASRM guidelines in exchange for appearing on the association’s website 
as preapproved agencies.21 Presence on this list currently serves as the only de facto 
regulatory mechanism of agency behavior, yet each agency’s actual compliance has never 
been formally verified by ASRM. One study found that of 66 egg donation and surrogacy 
agency websites on the list in 2008, 10 were noncompliant with ASRM guidelines in the 
form of trait-based payment and 3 in the form of inappropriately high compensation,2 but 
this study did not compare agencies and clinics in any specific way.2 Two studies of 
agencies, IVF clinics, and personal recruitment ads in college newspapers and on craigslist 
demonstrated that agencies were more likely than IVF clinics to compensate women more 
for preferable traits––directly violating ASRM guidelines––and were more likely to recruit 
between the ages of 18 and 20, which is inconsistent with ASRM’s suggested age minimum 
of 21.15,22 Another study of anonymity policies of clinic, egg agency, and sperm bank 
websites and brochures found that agencies appeared to show provider photographs, 
proactively inform egg providers of cycle outcomes, and offer nonanonymous matching 
options more frequently than did IVF clinics, although this study did not report whether any 
of these differences were statistically significant.23
These issues are of concern outside the U.S., too. Egg providers and recipients enter the U.S. 
from other countries for these services, since few countries explicitly permit payment for 
egg providers, resulting in global markets that have raised ethical concerns.24,25
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This paper thus aims to examine more fully differences between agencies and clinics. We 
also examine here critical additional issues and a larger sampling of websites (N = 128) than 
done previously (i.e., including sites that recruit, but do not mention trait-based provider 
compensation).
Materials and Methods
We systematically reviewed fertility clinics within the U.S. and agencies involved in 
recruiting of egg providers by analyzing Internet websites. To simulate the steps that 
prospective egg providers would take to find provision opportunities, we conducted an 
online search through the search engine Google, entering the term egg donation, in June 
2010. As shown in Figure 1, we collected a list of 414 websites from within the first 300 
results returned from Google. Within the first 20 results a large health directory website 
(www.ihr.com) appeared, as did websites of SART and ASRM. We included all IVF 
practice/clinic and agency websites listed on these 3 sites and removed any duplicate site 
that appeared on more than 1 of these sites. We also eliminated sites that were not directly 
related to the recruitment of egg providers (e.g., news articles and informational websites).
Three coders independently read a randomly selected sample of websites to familiarize 
themselves with website content and develop a systematic coding manual. Afterwards, every 
second website was selected from the master list, totaling 207. Two coders analyzed each of 
these 207 sites. Coders examined the websites independently for quality and quantitative 
data and compared results, discussing ambiguities in the coding to arrive at a consensus. In 
reviewing these 207 sites, we removed 13 that were not egg provider agencies or clinics 
(e.g., egg banks, research facilities, and affiliate networks. For the remaining 194 websites 
we coded the following broad categories: (1) Background Information: IVF clinic versus 
agency, and geographic region of the country,26 (2) Provider Eligibility Restrictions: 
minimum and maximum age for participation; minimum education requirements, (3) ASRM 
Endorsement: agency’s endorsement by ASRM (agencies) or membership in SART (clinical 
practices); whether site referred to ASRM guidelines when discussing compensation, (4) 
Compensation Structure: whether a site mentioned a compensation amount, offered a flat fee 
versus a range, noted its base minimum compensation as above or below $5,000, mentioned 
desirable traits, or offered an upfront bonus to register or a referral bonus for introducing 
another provider, (5) Egg Provider Privacy: whether a site required visitors to register before 
viewing the database of available providers, whether photos of providers were publically 
accessible, whether the site allowed providers and recipients to meet, and (6) Disclosure of 
Health Risks: any mention of short-term health risks (e.g., OHSS),27 any mention of 
psychological/emotional risks (beyond hormone related imbalances), any acknowledgement 
of an unknown or possible risk of cancer or any long-term risk to future fertility (e.g., via 
severe infection or ovarian torsion and tissue necrosis).28–30
We categorized websites as either “clinic” or “agency,” based on whether the recruitment 
web-page was housed within an IVF clinic or agency website. In some instances the 
recruitment page referred to the entity as an “agency” but either shared a domain name with 
an established IVF clinic or clearly directed the visitor to the IVF clinic’s website, in which 
case we categorized such websites as IVF clinics. We assessed the frequencies of website 
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characteristics across these two types of organizations and used a logistic regression to 
compare websites of agencies with those of clinics, and examined the strength of 
associations. We were not required to obtain Institutional Review Board approval as we did 
not collect data concerning any human subjects and assessed only publicly available 
websites. We have no conflicts of interest.
Results
As seen in Figure 1, of the 194 IVF clinic and agency examined, nearly two-thirds (N=128 
[66%]) actively recruited providers online (i.e., provided a registration form or a number to 
call). As shown in Table I, of these 128 sites 39.8% were agencies, 78.9% were SART 
members or ASRM approved, and 30.5% were in the Western U.S. Of the websites, 73.5% 
made no mention of ASRM ethical guidelines on financial compensation to egg providers, 
39.5% accepted providers under age 21, 48.3% limited a recruited provider’s age to ≤31, 
and 18.0% had a minimum educational requirement to provide eggs (high school or above), 
Of the websites, 78.9% indicated a compensation amount, of which 46.1% offered a range 
as opposed to a flat fee, 25.8% set a minimum amount > $5,000, 49.0% mentioned 
preferable provider traits, and 6.7% offered an up-front cash incentive to register or a 
referral bonus for introducing a new egg provider. Of the websites, 14.1% did not require 
online registration to view provider profiles, 7.8% provided unregistered public access to 
view photos of potential providers, and 23.9% facilitated providers’ and recipients’ meeting 
each other. Regarding donor risks, 62.5% did not discuss any short-term risks (e.g., OHSS, 
infection or hospitalization), 4.7% (all of which were clinics) acknowledged a possible risk 
of cancer, 92.2% did not mention risks to future fertility (e.g., damage to the ovaries), and 
78.1% did not mention possible emotional or psychological risks of egg provision.
Agencies were more likely than clinics to be based in the Western U.S. (41.2% vs. 23.4%, 
OR = 1.51, p < 0.034) and not be ASRM/SART approved (41.2% vs. 7.8%, OR = 8.28, p < 
0.001). Agencies were also more likely to refer to ASRM’s ethical compensation guidelines 
(51.0% vs. 2.0%, OR = 0.19, p < 0.001), set maximum provider age at ≤ 31 (70.8% vs. 
32.9%, OR = 4.96, p < 0.001), have a minimum education requirement to provide eggs 
(35.3% vs. 6.5%, OR = 7.86, p < 0.001), mention an egg provider compensation amount 
(98.0% vs. 66.2%, OR = 0.04, p < 0.002), offer a range of compensation as opposed to a flat 
fee (78.4% vs. 13.7%, OR = 22.86, p < 0.001), list a minimum compensation amount > 
$5,000 (37.3% vs. 18.2%, OR = 2.67, p < 0.018), and mention preferable provider traits 
(76.5% vs. 21.6%, OR = 11.82, p < 0.001). Agencies were more likely to discuss short-term 
risks like OHSS or infection (52.9% vs. 27.3%, OR = 0.33, p < 0.004) and to allow 
providers and recipients to meet (39.6% vs. 12.3%, OR = 4.67, p < 0.001). Clinics were 
more likely than agencies to acknowledge an unknown, possible risk of cancer (7.8% vs. 
0%, respectively, p < 0.041). While not statistically significant, only 25.5% of agencies vs. 
19.5% of clinics mentioned psychological/emotional risks, and 11.8% vs. 5.2%, 
respectively, mentioned risk to future fertility.
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This study, the first to examine systematically risk disclosures, eligibility requirements, 
mention of professional guidelines, and key aspects of the compensation structure in 
comparing egg provider agency and clinic recruitment websites in the U.S., suggests key 
differences in how these two entities operate. Specifically, clinics and agencies appear to 
differ in compliance with published ASRM guidelines and, more broadly, in ethical issues 
related to online recruitment. Agencies are more likely than clinics to violate ASRM 
guidelines about not only compensation for time and inconvenience, as opposed to the eggs 
themselves (as previously reported), but also to display compensation amounts online, to let 
the amount fluctuate, and to set the minimum > $5,000––the threshold above which ASRM 
claims that payment “requires justification.”1,2,15
While previous research found that agencies are more likely than clinics to pay premiums 
for preferable traits (e.g., beauty, academic pedigree, ethnicity) and for proven fertility or 
tolerance of the egg donation process,1,15 the present data examines a broader array of 
practices (e.g., whether compensation is displayed, fixed, above the $5,000 threshold, and 
contingent upon the egg provider’s education). Agencies appear more likely not only to 
compensate women for their time, but to vary prices based on market demand and to offer 
ethically questionable higher sums without a case-specific justification.
Clinics are often associated with academic medical centers and inevitably involve 
physicians. Agencies may thus be more likely than IVF clinics to discuss short-term and 
long-term risks in order to gain trust from physicians and clinics that might refer patients. 
Agencies are also more likely than clinics to refer to ASRM guidelines on compensation—
perhaps to be seen as ethically responsible by website viewers. In contrast, ART physicians 
are expected to follow higher professional standards and may thus feel less need to state 
regulations explicitly on their websites. Agencies also may discuss risks more frequently 
because they also specify compensation amounts more often. ASRM guidelines state that 
advertisements presenting financial or other benefits should also present risks and burdens.6 
In contrast, clinics may feel less compelled to discuss risks online because they are also less 
likely to discuss compensation there. Clinics also may see discussion of risks as premature, 
since they are the ones prescribing the medications and conducting the procedures and thus 
anticipate discussing the risks in person.
Agencies’ greater likelihood of setting an age ceiling of ≤31 years suggests that agencies 
may seek to build an egg provider population with more ideal, marketable characteristics, 
since women’s fertility begins to decline at age 32.31 Many infertile women looking for egg 
providers will know that increasing age is associated with declining fertility; indeed, these 
women may themselves be seeking eggs as a result of age-related infertility. However, 
agencies’ tendency to set the age maximum for providers at ≤31 years could also be seen as 
biased against women aged >31 who may still be reasonably fertile and viable egg 
providers.
Agencies are more likely to require a minimum level of education in order to provide eggs. 
This requirement may reflect traits that recipients often seek in egg providers, and beliefs 
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that intelligence is substantially genetic. This finding may underscore the notion that egg 
provision agencies look for “sellable” qualities in providers.32
Agencies are more likely to be in the Western U.S., consistent with previous findings on 
regional variations in egg provision practices in the U.S. Two studies have reported that egg 
providers are more likely to receive higher compensation in the West.2,30 Our previous 
study found that websites located in the West are more likely to base compensation upon 
traits.1 These findings do not establish a causal link between the greater number of agencies 
and higher compensation amounts in the West, but suggest that the West may have a more 
market-driven egg provider environment.
Previous research has found that agencies were more likely than clinics to give egg 
providers the option of being nonanonymous.23 Our data supports this finding, while also 
indicating that this difference may arise from agencies’ sole, primary identity and function 
as businesses, rather than also providing treatment and care as clinics do. The fact that 
agencies more than clinics now allow nonanonymous egg provision may demonstrate a 
more flexible approach, presumably geared toward intended parents’ desires. This openness 
in the matchmaking process may appeal to intended parents who want to evaluate egg 
providers as much as possible, not just through minimal online profiles.
These data have several implications for future practice and possible policy. Our findings 
suggest possible needs for more professional guidelines, oversight, or monitoring regarding 
agencies, including better incentives for them to follow guidelines, given their higher 
likelihood to deviate in certain ways. Since agencies are free-standing entities, without 
necessarily having any licensed healthcare providers involved, their oversight poses a 
unique challenge to the fertility industry. Efforts could be made to expand the number of 
agencies that agree with SART to follow ASRM guidelines regarding oocyte donation. 
Currently, SART offers agencies, as an incentive for agreeing, listing on ASRM and SART 
websites. But other, stronger incentives, motivations or penalties could be offered. The 
agreement might include willingness to be randomly audited by ASRM and/or rewarded for 
compliance.
Agencies could also be consulted concerning ways of increasing compliance with ASRM 
guidelines and factors motivating noncompliance. Agencies have acknowledged the pressure 
to offer egg providers high compensation in order to remain competitive in the recruitment 
landscape.30 If true, ASRM may benefit from understanding these challenges from agency 
perspectives. Extending a collaborative dialogue to other stakeholders (e.g., egg providers, 
intended parents, and even adults born from third-party egg providers) might also be 
beneficial.
Our findings indicate several areas for further research: to improve monitoring and aid in 
consideration of further possible guidelines and/or regulation. Research can examine the 
proportion of egg providers recruited through agencies versus clinics, assessing different 
recruitment pathways. Studies could investigate the paths that intended parents follow in 
approaching agencies and/or clinics. For example, if a fertility clinic does not recruit oocyte 
providers, how often does it refer potential egg recipients to agencies? Our data suggest this 
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scenario is likely, since 47% of clinics did not recruit egg providers online. Such clinics 
might refer prospective parents to ASRM-approved or other, compliant agencies or simply 
use the business value of the referral relationship to encourage agencies to improve 
practices.
Studies of egg providers, such as whether they simultaneously provide eggs through 
multiple clinics and agencies, and perhaps their own personal advertising, are also 
important. Research can probe, too, other aspects of the business and financial relationships 
between clinics and agencies. Some clinics or physicians may have financial stakes in 
agencies, generating conflicts of interest between market-oriented agencies and duty-bound 
clinics. Research can also assess the effectiveness of ASRM’s existing regulatory practices, 
comparing the recruitment and compensation behaviors of SART-affiliated versus 
independent IVF clinics. Research might also investigate the behavior of agencies listed on 
SART’s website that have signed the agreement versus those that have not.
Our study has several potential limitations. We collected data from agency and clinic 
websites, and information on the websites may differ from actual practices. A list of 
websites could have been compiled alternatively, potentially using searches for keywords 
other than egg donation (e.g., selling eggs) or using classified ads.
Nonetheless, this study provides the first systematic data on how agencies differ from IVF 
clinics in key aspects of their websites’ compensation, communication practices, and 
compliance with guidelines. This research thus has important implications for future 
practice, research, and possible guidelines.
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Summary of recruitment websites surveyed.
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